Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Unusual challenges in clinical oncology: YO case discussions

YO14 - Parotid Gland Salivary Duct Adenocarcinoma: New targets for new times


03 Dec 2022


Unusual challenges in clinical oncology: YO case discussions


Pathology/Molecular Biology;  Targeted Therapy;  Molecular Oncology

Tumour Site

Head and Neck Cancers


Clara Garcia Gonzalez


C. Garcia Gonzalez1, A.J. Cunquero Tomas2, L. Sanz Monge1, J. Garrido Gallego1, A. Berrocal1

Author affiliations

  • 1 Medical Oncology Department, CHGUV - Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 2 Medical Oncology Dept., Servicio de Oncología Médica, Hospital General de Requena, Valencia, España., 46340 - Valencia/ES


Login to access the resources on OncologyPRO.

Abstract YO14

Case summary

Case report

56-year-old man diagnosed in January 2019 with parotid ductal-type adenocarcinoma E-IVA (pT1 pN3b cM0) after complete parotidectomy with left functional dissection. Adjuvant treatment with platinum-based chemoradiotherapy was planned, but patient declined and preferred surveillance. 16 months later, in June 2020, locoregional and lung progression was observed in CT-scan. First line treatment with Carboplatin-Paclitaxel was started, achieving partial response after 6 cycles. In May 2021, after 6-month follow-up, CT-scans show new lung disease progression. 2nd line treatment with 6 cycles of Adriamycin delivered a stable disease. In January 2022 pulmonary progression was confirmed. On no possibility of tumor rebiopsy, primary tumor tissue was deeply reanalyzed: Next Generation Sequencing (NGS) showed PIK3CA and TP53 mutations; and immunohistochemistry (IHC), overexpression of HER2, with negative expression of estrogen (ER) and progesterone (PR) receptors. Trastuzumab + Pertuzumab was started in February 2022. After 3 cycles, with good tolerance to treatment without relevant toxicities, re-evaluation CT confirmed progression of lung disease. Upon request of the patient, who remains asymptomatic, considering a slow progressing disease, a watch and wait strategy has been adopted, and further treatment options (alpelisib, capecitabine…) would be discussed when necessary.


Although chemotherapy has been considered standard of care in salivary gland carcinomas (SGC), different subtypes harbor different molecular alterations, potentially actionable. HER2 overexpression in SGD ranges from 15% to 44%, with recurrence, distant metastases, and poorer survival rates. Recent studies show improvement in tumor control rate and prognosis of SGC HER2+ by adding trastuzumab to treatment as monotherapy or in combination with chemotherapy and/or pertuzumab. Other alterations such as PI3K mutations have been reported in up to 53% of SGC cases, conferring a potentially beneficial and yet poorly explored therapeutic strategy in SGC.

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.